Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure.

ABSTRACT

Aim: To investigate the temporal evolution of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9), low-density lipoprotein receptor (LDLR) and myeloperoxidase (MPO) in relation to clinical outcome in chronic heart failure (CHF). Methodology & results: Trimonthly blood sampling was performed during a median follow-up of 2.2 (IQR 1.4-2.5) years in 263 CHF patients. Seventy patients reached the primary end point (PE) (cardiovascular death, heart transplantation, left ventricular assist device implantation or HF-hospitalization). MPO level was independently associated with the PE; the adjusted (for clinical factors) hazard ratio (aHR) per standard deviation difference in MPO was 1.71 (95% CI 1.23-2.43) at any time during follow-up. PCSK9 level (HR 1.45 [1.04-2.06]) and LDLR (HR 0.66 [0.49-0.87]) were statistical significantly associated with the PE but only in unadjusted analyses. Slope of temporal MPO evolution (aHR 1.34 [1.12-1.76] per 0.1 standard deviation/year difference in slope) and LDLR (aHR 0.78 [0.61-0.90]) however, were associated with PE. Conclusion: Temporal patterns of MPO and LDLR are independently associated with clinical outcome in CHF, which illustrates the importance of assessing temporal evolutions. Clinical trial registration information registered in ClinicalTrials.gov, number NCT01851538. https//clinicaltrials.gov/ct2/show/NCT01851538.